Arbutus Biopharma Logo
Tekmira Expands Product Pipeline With RNAi Therapeutic for the Treatment of Alcohol Dependence
01 mars 2012 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 1, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Updates Financial Guidance: Cash Runway Further Extended Into Second Half of 2013
29 févr. 2012 23h57 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, has updated its...
Arbutus Biopharma Logo
Tekmira Announces USPTO Issuance of Key Patents Broadly Covering LNP Formulations and Mitigation of Immune Stimulation
09 févr. 2012 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that the...
Arbutus Biopharma Logo
Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical Trial
08 févr. 2012 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Arbutus Biopharma Logo
Tekmira Provides Periodic Update to Litigation
17 janv. 2012 16h32 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Arbutus Biopharma Logo
Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia
10 janv. 2012 16h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today...
Arbutus Biopharma Logo
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
04 janv. 2012 16h03 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Arbutus Biopharma Logo
Tekmira Provides Periodic Update to Litigation
21 déc. 2011 17h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Arbutus Biopharma Logo
Tekmira Secures $3 Million Financing
21 déc. 2011 16h50 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced it...
Arbutus Biopharma Logo
Tekmira Pharmaceuticals Receives Approval from FDA to Initiate TKM-Ebola Phase 1 Clinical Trial
28 nov. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...